BioWorld

March 4, 2010

View Archived Issues

After Trauma, Mitochondrial DNA Set Off Sepsis-Like Response

Read More

Ataluren's DMD Expedition Hits Bump with Failed Phase IIb Trial

Read More

NiCox, Bausch & Lomb Ink $179.5M Deal in Glaucoma

Read More

Clinic Roundup

Read More

Stock Movers for March 4, 2010

Read More

Other News To Note

Read More

Financings Roundup

Read More

Medivation Rocked by Dimebon Miss in Late-Stage AD Study

Shares in Medivation Inc. fell 67.5 percent Wednesday on news that its Phase III trials of Alzheimer's drug candidate Dimebon missed all of the study's stated goals, smashing some high hopes on Wall Street. (BioWorld Today) Read More

ExonHit Emerges a Winner in Allergan, BMS Pain Deal

Read More